Telehealth company Hims & Hers is facing a growing number of U.S. investor lawsuits after Novo Nordisk's decision last month ...

Novo Nordisk holds 72% international and 50%+ U.S. market share in GLP-1 treatments, serving 46 million patients globally.

A woman on Ozempic has revealed why she gave her 11 year old daughter weight loss jabs, a similar drug called Wegovy, on This Morning ...

Hims & Hers Health Inc. board members and executives failed to tell shareholders that its Novo Nordisk A/S Wegovy ...

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

A MOTHER who put her daughter on weight loss jabs at the age of 11 has opened up on her family’s experience with the ...

National shareholders rights firm Hagens Berman continues to investigate the legal claims and urges Hims & Hers investors who suffered substantial losses to submit your losses now . The firm also ...

We can't have it both ways. If we want more cutting-edge drugs, we have to protect the property rights that make them ...

Key Points Hims & Hers Health is entering the Canadian market.The company will offer a generic version of semaglutide in the ...

It’s a controversial topic… Should we give weight-loss jabs to kids? Over in America, we meet mum Ashley Hamilton, who’s allowed her daughter, Sophia, to use Wegovy since she was just 11 years old.

Hims & Hers (HIMS) stock in focus as the company faces a growing number of lawsuits following Novo Nordisk's (NVO) decision ...

More than one-third of people who helped develop the 2023 guidelines for treating children with obesity had undisclosed ...